Drug Trial Radar · NCT01105091
Epoprostenol for Injection in Pulmonary Arterial Hypertension
Last checked: Nov 20, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Mar 2010
Primary completion
May 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 16, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multi-center, open-label, randomized, Phase IV exploratory study comparing safety, tolerability, pharmacokinetics, and effectiveness of ACT-385781A and Flolan (epoprostenol sodium) in patients with pulmonary arterial hypertension who are naïve to injectable prostanoid treatment and in need of such treatment. Approximately 30 patients from 8 U.S. clinical sites will be randomized to receive either ACT-385781A or Flolan (2:1 respectively) for 28 days of treatment.
Conditions
- Pulmonary Arterial Hypertension
Interventions
ACT-385781A (Actelion Epoprostenol)Drug
per Prescribing Information
Flolan®Drug
Per Prescribing Information
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Normalized Pharmacokinetics of 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha at 2 ng/kg/MinTime frame: Day 1
- Dose Normalized Pharmacokinetics of 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha at 4 ng/kg/MinTime frame: Day 1
- Dose Normalized Pharmacokinetics of 6-keto-Prostacyclin F1alpha at 2 ng/kg/MinTime frame: Day 1
- Dose Normalized Pharmacokinetics of 6-keto-Prostacyclin F1alpha at 4 ng/kg/MinTime frame: Day 1
- Six-minute Walk Distance (6MWD) - Baseline and Day 28Time frame: Baseline and 28 days (+3 days)
- Patients With New York Heart Association (NYHA) Functional Class Change (Improved or Worsened) From Baseline to Day 28Time frame: From baseline to 28 days (+3 days)
- Percentage Central Venous Blood Oxygen Saturation (ScVO2) - Baseline and Day 28Time frame: Baseline and 28 days
- Blood Pressure - Baseline and Day 28Time frame: Baseline and 28 days
- Heart Rate - Baseline and Day 28Time frame: Baseline and 28 days
- Body Weight - Baseline and Day 28Time frame: Baseline and 28 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.